GSK aims for 14 new drug candidates by 2014

Hannah Blake


GlaxoSmithKline has announced it will be moving towards a broader range of drugs than it has developed in the past, in a move away from the industry’s traditional “blockbusters” focus. The global drugmaker recently released details of its pipeline, which shows that the company expects to have essential clinical trial data on 14 medicines by 2014.

“We feel very comfortable, particularly through 2013 and into 2014, that we can manage both with a broadly flat R&amp,D budget and also without significant increases in our commercial organization.”

Andrew Witty, Chief Executive of GSK.

This new clinical trial data could change the way some diseases are treated – particularly in the heart disease and cancer areas. Phase 3 clinical trials of GSK’s heart drug, darapladib, and therapeutic cancer vaccine, MAGE-A3, which is being tested in lung cancer and melanoma, are due to finish in 2014. Both drugs are potentially high-reward, but also high-risk, because they represent new medical approaches.




Related news:

GSK hopes for 14 new drug successes in 2013-14 (Reuters)

GlaxoSmithKline details hopes for 14 pipeline drugs in 2013/14 (Economic Times)

Don't miss your daily pharmaphorum news.
SUBSCRIBE free here.